For Newly Diagnosed & Recurrent Glioblastoma Patients
Precision Strategy for Glioblastoma
Understand your tumor biology and design a personalized treatment strategy.
Glioblastoma behaves differently in every patient. We analyze tumor biology, metabolic vulnerabilities, and immune signals to design a personalized treatment protocol — not a one-size-fits-all approach.
Developed by the research team at Art of Healing Cancer.
Supporting patients worldwide with integrative precision oncology.
Why a Precision Approach Matters
Unique Tumor Biology
Every glioblastoma tumor has distinct molecular drivers that demand a tailored approach.
Beyond Standard Treatment
Standard protocols remain largely uniform — precision analysis can reveal better options.
Precision Tumor Intelligence
Advanced tumor profiling reveals new therapeutic opportunities specific to your case.
Why Standard Care Falls Short
Glioblastoma is the most aggressive primary brain tumor in adults. The current standard of care — the Stupp Protocol — has remained essentially unchanged for nearly two decades. Every GBM is molecularly unique, yet most patients receive the same treatment.
15 months
Median Survival
Under standard care — a timeline that has barely changed in two decades.
~100%
Recurrence Rate
Nearly all patients experience tumor recurrence. No standard of care exists for recurrent GBM.
Only 1
FDA-Approved Chemo Drug
Temozolomide remains the only FDA-approved chemotherapy for newly diagnosed GBM.
Every GBM
Is Molecularly Unique
Yet most patients receive the same one-size-fits-all protocol.
Intelligence Before Intervention
The Intelligence Layer is our methodology. Before designing any treatment, we build comprehensive biological intelligence about the individual patient's tumor.
You cannot fight what you don't understand — and every GBM is a unique biological entity with its own vulnerabilities and resistance architecture.
From the CSF
Cerebrospinal Fluid Analysis
Post-surgery, we extract circulating glioblastoma cells from the patient's CSF using advanced liquid biopsy techniques. From these cells, we generate:
Drug Sensitivity Testing
Which chemotherapies, targeted agents, and natural substances the tumor actually responds to
Transcriptomic Profiling
Gene expression data revealing active signaling pathways
Monoclonal Antibody Sensitivity
Which immunological agents may work
Small Molecule Inhibitor Mapping
Which precision drugs can target specific vulnerabilities
Natural Substance Sensitivity
Which plant-derived and biological compounds show efficacy
From the Tissue Block
Post-Surgery Tumor Analysis
The tumor tissue block obtained post-surgery is used for comprehensive genomic and transcriptomic profiling:
Whole Exome Sequencing (WES)
Identifying all coding mutations, copy number alterations, and structural variants
Transcriptome Sequencing (RNA-Seq)
Understanding gene expression patterns and pathway activation
Variant-to-Pathway Mapping
Mapping mutations to their functional signaling networks
Actionability Analysis
Every identified alteration evaluated for druggable targets
Therapeutic Intelligence Map
These two data streams converge into a comprehensive document that informs the treating physician about what the tumor is, how it behaves, and what it is vulnerable to. Only then do we design a treatment protocol.
A Multi-Modal, Precision-Driven Protocol
Based on the Intelligence Layer, we deploy a combination treatment approach. Each patient's protocol is different, but it draws from these categories:
We use chemotherapy, but we don't guess. Drug sensitivity testing guides the selection. Agents that may be used include:
Temozolomide (TMZ)
Gold standard alkylating agent, effectiveness dependent on MGMT methylation status
Lomustine (CCNU)
Nitrosourea used at recurrence or combined with TMZ for MGMT-methylated tumors
Carmustine (BCNU)
Delivered systemically or as Gliadel wafers placed into the resection cavity
Procarbazine
Part of the PCV regimen used in certain molecular subtypes
Vincristine
Vinca alkaloid used in the PCV combination regimen
Irinotecan
Topoisomerase inhibitor, sometimes combined with Bevacizumab
Carboplatin
Platinum-based agent explored in recurrent settings
Etoposide
Topoisomerase II inhibitor used in select recurrent cases
Low-dose metronomic regimens — continuous low-dose chemotherapy targeting tumor angiogenesis and immune modulation — may also be employed.
Starving the Tumor, Fueling the Body
Metabolic therapy starts on your plate. The ketogenic diet is a foundational pillar — treated as a precision-dosed metabolic intervention, monitored with the same rigor as any drug protocol.
The Ketogenic Diet for GBM
Fat
Olive oil, MCT oil, avocado, nuts, ghee
Protein
Eggs, fish, poultry, grass-fed meats
Carbs
Low-glycemic vegetables, leafy greens only
The Rollout Diet
Pre-Ketosis Preparation
Gradually reduce carbs to ~50g/day. Eliminate processed sugars and refined grains. Begin blood glucose tracking with CGM. Baseline labs: fasting glucose, insulin, lipid panel, HbA1c.
Therapeutic Fasting Entry
Medically supervised 3-5 day water-only fast to deplete glycogen stores. Blood glucose drops to 55-65 mg/dL. Ketones rise above 1.0 mmol/L. Specifically timed around treatment cycles.
Ketogenic Maintenance
Well-formulated ketogenic diet with 5 small meals/day. Twice-daily glucose and ketone monitoring. Weekly check-ins with ketogenic-trained nutritionist. Mediterranean-style approach preferred.
Periodic Pulse Fasting
Scheduled 24-72 hour therapeutic fasts timed around chemo/radiation cycles. Deepens ketosis and glucose restriction. Enhances differential stress sensitization.
The Glucose Ketone Index (GKI)
GKI = Blood Glucose (mmol/L) ÷ Blood Ketones (mmol/L). A single number capturing your metabolic state.
No therapeutic effect. Where most people on a normal diet live.
Some metabolic benefit. Glucose supply reduced but not therapeutically managed.
Target zone. Meaningful metabolic stress on the tumor while protecting normal brain cells.
Maximum metabolic pressure on the tumor. Achieved during prolonged fasting or strict protocols.
Published case: A 64-year-old woman with IDH-wildtype glioblastoma maintained a GKI of 1.65 during year one and 2.02 during year two. She experienced complete clinical improvement with no visible tumor progression on MRI. When life stress raised her GKI to 3.20 in year three, slow tumor progression was observed.
We teach every patient and caregiver how to monitor and optimize their GKI as part of our protocol.
Your Journey With Us
Surgery
Maximal safe resection by the neurosurgeon. Tissue block is preserved.
Intelligence Building
CSF collection + tissue block sent for comprehensive profiling (WES, RNA-Seq, drug sensitivity, etc.)
Therapeutic Intelligence Map
All data synthesized into a single document mapping the tumor's vulnerabilities.
Protocol Design
In collaboration with the treating oncologist, a personalized multi-modal protocol is designed.
Treatment & Monitoring
Protocol deployed with continuous monitoring and adaptation based on response.
Every GBM Is Different. Your Treatment Should Be Too.
We work WITH your treating physician, not in place of them.
The Intelligence Layer is a decision-support tool that gives doctors the deepest possible understanding of the tumor.
This is not alternative medicine — it is precision oncology integrated with evidence-based metabolic and complementary approaches.